SonoStem Technologies, Inc. is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class targeted gene therapeutics platform for tissue regeneration. Our technology builds upon more than 30 years of scientific research during which we investigated a myriad of cell and gene therapies for various diseases and selected the most promising ones.
SonoStem’s lead therapeutic candidate, SonoHeal-RBF (Rapid Bone Formation), is an “off-the-shelf” gene therapy product that is currently in pre-IND stages of development for the treatment of severe long bone fractures. Pre-clinical work and FDA meetings completed a need to raise capital to engage regulatory consultant and submit FDA application. SonoHeal-RBF acts in a 2-step procedure. First, the patient’s own stem cells are recruited to the fracture site using a biodegradable matrix. Next, the recruited cells are activated to form new bone by an ultrasound-based therapeutic gene delivery. Based on our pre-clinical data, estimated fracture healing time is 8 weeks with 100% success rate and no complications versus 16 weeks and an approximate 81% success rate with current commercially available therapies.
Below is a link to the animation explaining SonoHeal-RBF.
http://sonostem.com/#animation
SonoStem’s long term vision is to be a leading bio-surgical platform technology company focused on addressing various unmet clinical needs. The company is using its core technology to develop additional innovative products to treat spinal disorders, soft tissue tears, craniofacial bone loss and thrombosis.
Ready to Ask For Funding for your company?
Post a Funding Request